Login   |  Users Online: 1898 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
Search Article 
  
Advanced search 
   Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts
PHARMACOLOGICAL STUDY
Year : 2019  |  Volume : 40  |  Issue : 1  |  Page : 58-63

Anticancer activity of Yashada Bhasma (bioactive nanoparticles of zinc): A human pancreatic cancer cell line study


1 Department of Rasasastra and Bhaishajya Kalpana, IPGT and RA, Gujarat Ayurved University, Jamnagar, Gujarat, India
2 Department of Radiotherapy, Government Medical College, Kozhikode, Kerala, India

Correspondence Address:
Seetha Chandran
Department of Rasasastra and Bhaishajya Kalpana, IPGT and RA, Gujarat Ayurveda University, Jamnagar -361 008, Gujarat
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ayu.AYU_239_17

Rights and Permissions

Background: Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer-related mortality. Efforts to improve cancer treatment through nanotechnology are at the developmental stage, and it will be gracious if the drug with anticancer property itself is a nanoparticle. Bhasma is organomineral complexes which are bioactive nanoparticles. Yashada Bhasma (incinerated processed zinc) is widely used in Ayurveda for various diseases, and there are evidence that ZnO nanoparticles are promising antitumor agent. However, no studies have been conducted on the effectiveness of Yashada Bhasma in pancreatic cancer. Materials and Methods: Two types of test drugs, Parada Marita Yashada Bhasma(PMY) and Vanaspati Jarita Marita Yashada Bhasma (JMY), were prepared as per the guidelines of pharmaceutics of Ayurveda. Particle size analyses of Yashada Bhasma and Zeta potential study was carried out initially. Further human pancreatic cancer cell line (MIA PaCa-2) study was done using in vitro sulforhodamine B assay, keeping adriamycinas control. After 48 h of incubation, antiproliferative effects were assessed. Results: JMY and adriamycin showed dose-dependent growth inhibition of cancer cells. Both Yashada Bhasma samples showed a cytostatic effect at this concentration. Conclusion: The study leads to new avenues for cancer treatment by developing such unique and highly effective bioactive nano-sized therapeutic agent.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed145    
    Printed1    
    Emailed0    
    PDF Downloaded96    
    Comments [Add]    

Recommend this journal